{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:45:21Z","timestamp":1793825121990,"version":"4.6.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jchromb.2024.124100","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T15:47:27Z","timestamp":1711468047000},"page":"124100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Simultaneous determination of 11 oral targeted antineoplastic drugs and 2 active metabolites by LC-MS\/MS in human plasma and its application to therapeutic drug monitoring in cancer patients"],"prefix":"10.1016","volume":"1237","author":[{"given":"Jing","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongming","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furong","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2024.124100_b0005","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","article-title":"Molecular targeted therapy: treating cancer with specificity","volume":"834","author":"Lee","year":"2018","journal-title":"Eur J Pharmacol."},{"key":"10.1016\/j.jchromb.2024.124100_b0010","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00228-020-03014-8","article-title":"Therapeutic drug monitoring of oral targeted antineoplastic drugs","volume":"77","author":"Mueller-Schoell","year":"2021","journal-title":"Eur J Clin Pharmacol."},{"key":"10.1016\/j.jchromb.2024.124100_b0015","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/bcp.14678","article-title":"Role of TDM-based dose adjustments for taxane anticancer drugs","volume":"87","author":"Muth","year":"2021","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.jchromb.2024.124100_b0020","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.clcc.2018.09.006","article-title":"Bolus 5-fluorouracil (5-FU) in combination with oxaliplatin is safe and well tolerated in patients who experienced coronary vasospasm with infusional 5-FU or capecitabine","volume":"18","author":"Chakrabarti","year":"2019","journal-title":"Clin Colorectal Cancer."},{"key":"10.1016\/j.jchromb.2024.124100_b0025","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1007\/s00432-013-1480-7","article-title":"Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai","volume":"139","author":"Cai","year":"2013","journal-title":"J Cancer Res Clin Oncol."},{"key":"10.1016\/j.jchromb.2024.124100_b0030","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ctrv.2010.08.006","article-title":"Moving towards dose individualization of tyrosine kinase inhibitors","volume":"37","author":"Klumpen","year":"2011","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.jchromb.2024.124100_b0035","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s12032-010-9541-0","article-title":"The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib","volume":"28","author":"Zhao","year":"2011","journal-title":"Med Oncol."},{"key":"10.1016\/j.jchromb.2024.124100_b0040","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/FTD.0000000000000004","article-title":"Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care","volume":"36","author":"Lankheet","year":"2014","journal-title":"Ther Drug Monit."},{"key":"10.1016\/j.jchromb.2024.124100_b0045","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15123233","article-title":"Dose optimization in oncology drug development: the emerging role of pharmacogenomics, pharmacokinetics, and pharmacodynamics","volume":"15","author":"Papachristos","year":"2023","journal-title":"Cancers (basel)."},{"key":"10.1016\/j.jchromb.2024.124100_b0050","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1002\/jps.24113","article-title":"Enzyme- and transporter-mediated drug interactions with small molecule tyrosine kinase inhibitors","volume":"103","author":"Shao","year":"2014","journal-title":"J Pharm Sci."},{"key":"10.1016\/j.jchromb.2024.124100_b0055","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41397-020-0152-7","article-title":"Effect of genetic polymorphisms in CYP3A4, CYP3A5, and m-TOR on everolimus blood exposure and clinical outcomes in cancer patients","volume":"20","author":"Bonnet","year":"2020","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.jchromb.2024.124100_b0060","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1124\/dmd.122.000929","article-title":"Bioavailability and pharmacokinetics of endoxifen in female rats and dogs: evidence to support the use of endoxifen to overcome the limitations of CYP2D6-mediated tamoxifen metabolism","volume":"51","author":"Koubek","year":"2023","journal-title":"Drug Metab Dispos."},{"key":"10.1016\/j.jchromb.2024.124100_b0065","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1677\/joe.0.0750305","article-title":"A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity","volume":"75","author":"Jordan","year":"1977","journal-title":"J Endocrinol."},{"key":"10.1016\/j.jchromb.2024.124100_b0070","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.clinthera.2007.07.022","article-title":"Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors","volume":"29","author":"Adams","year":"2007","journal-title":"Clin Ther."},{"key":"10.1016\/j.jchromb.2024.124100_b0075","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/cpt.787","article-title":"Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology","volume":"102","author":"Verheijen","year":"2017","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.jchromb.2024.124100_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2021.122752","article-title":"Simultaneous and rapid determination of 12 tyrosine kinase inhibitors by LC-MS\/MS in human plasma: application to therapeutic drug monitoring in patients with non-small cell lung cancer","volume":"1175","author":"Zhou","year":"2021","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"10.1016\/j.jchromb.2024.124100_b0085","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00216-020-03031-7","article-title":"Development and validation of a sensitive liquid chromatography tandem mass spectrometry assay for the simultaneous determination of ten kinase inhibitors in human serum and plasma","volume":"413","author":"Aghai","year":"2021","journal-title":"Anal Bioanal Chem."},{"key":"10.1016\/j.jchromb.2024.124100_b0090","unstructured":"U.S. Food and Drug Administration, Guidance for Industry: Bioanalytical Method Validation, 20https:\/\/www.fda.gov\/media\/70858\/download (accessed 4 Jan, 2024)."},{"key":"10.1016\/j.jchromb.2024.124100_b0095","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jchromb.2018.11.030","article-title":"Validation and clinical application of an LC-MS\/MS method for the quantification of everolimus using volumetric absorptive microsampling","volume":"1104","author":"Verheijen","year":"2019","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"10.1016\/j.jchromb.2024.124100_b0100","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00280-021-04286-2","article-title":"Exploratory analysis of target concentration of lenvatinib in the treatment of hepatocellular carcinoma","volume":"88","author":"Noda","year":"2021","journal-title":"Cancer Chemother Pharmacol."},{"key":"10.1016\/j.jchromb.2024.124100_b0105","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00280-016-3069-8","article-title":"A phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in chinese patients with advanced solid tumors","volume":"78","author":"Cao","year":"2016","journal-title":"Cancer Chemother Pharmacol."},{"key":"10.1016\/j.jchromb.2024.124100_b0110","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/jcph.1042","article-title":"Pharmacokinetics of osimertinib in chinese patients with advanced NSCLC: a phase 1 study","volume":"58","author":"Zhao","year":"2018","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.jchromb.2024.124100_b0115","doi-asserted-by":"crossref","DOI":"10.1007\/s10637-021-01115-4","article-title":"Pharmacokinetics of the oral multikinase inhibitor regorafenib and its association with real-world treatment outcomes","author":"Fukudo","year":"2021","journal-title":"Invest New Drugs."},{"key":"10.1016\/j.jchromb.2024.124100_b0120","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1349-7006.2007.00648.x","article-title":"Phase I study of sorafenib in japanese patients with hepatocellular carcinoma","volume":"99","author":"Furuse","year":"2008","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jchromb.2024.124100_b0125","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1111\/j.1349-7006.2008.00837.x","article-title":"Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, japanese patients with advanced refractory solid tumors","volume":"99","author":"Minami","year":"2008","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jchromb.2024.124100_b0130","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1080\/0284186X.2020.1759826","article-title":"The value of sorafenib trough levels in patients with advanced hepatocellular carcinoma - a substudy of the SORAMIC trial","volume":"59","author":"Labeur","year":"2020","journal-title":"Acta Oncol."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023224001089?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023224001089?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T19:19:43Z","timestamp":1712690383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023224001089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":26,"alternative-id":["S1570023224001089"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2024.124100","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simultaneous determination of 11 oral targeted antineoplastic drugs and 2 active metabolites by LC-MS\/MS in human plasma and its application to therapeutic drug monitoring in cancer patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2024.124100","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"124100"}}